[Effect of the estrogen-progesterone combination preparations gravistat and Minisiston on carbohydrate metabolism].
The effect of the estrogen-progesteron-combinations Gravistat (0.05 mg ethynylestradiol and 0.125 mg levonorgestrel) on glucose tolerance and plasma insulin was studied before and after tree and twelve months of treatment. In each case ten young fertile women participated in this study with aged 19 to 34 years. The fasting blood glucose and the glucose tolerance did not differ significantly under Gravistat and Minisiston. Reversible changes in the carbohydrate tolerance are most pronounced during the adaptations phase. The plasma insulin levels was no changed statistically under Gravistat and Minisiston.
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D003277:Contraceptives, Oral, Combined / Q000009:adverse effects*; D003280:Contraceptives, Oral, Synthetic / Q000009:adverse effects*; D004040:Dietary Carbohydrates / Q000378:metabolism; D004997:Ethinyl Estradiol / Q000009:adverse effects*; D019304:Ethinyl Estradiol-Norgestrel Combination; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007328:Insulin / Q000097:blood*; D016912:Levonorgestrel; D009644:Norgestrel / Q000009:adverse effects*
D001786:Blood Glucose; D003277:Contraceptives, Oral, Combined; D003280:Contraceptives, Oral, Synthetic; D004040:Dietary Carbohydrates; D007328:Insulin; D009644:Norgestrel; D004997:Ethinyl Estradiol; D016912:Levonorgestrel; D019304:Ethinyl Estradiol-Norgestrel Combination
Die Wirkung der Estrogen-Gestagen-Kombinationspräparate Gravistat und Minisiston auf den Kohlehydratstoffwechsel.